Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 In vitro antimicrobial and anticancer screening of the synthesized derivatives (126)

From: Benzoxazole derivatives: design, synthesis and biological evaluation

Comp. no. Antimicrobial screening (MIC = ×10−3 µM) Anticancer screening (IC50 = µM)
BS PA EC ST KP AN CA HCT-116
1 2.83 2.83 2.83 2.83 2.83 5.66 0.34 192.5
2 2.65 2.65 5.30 5.30 5.30 5.30 0.66 84.8
3 2.65 2.65 2.65 2.65 2.65 2.65 0.66 > 212.1
4 2.49 4.98 2.49 4.98 2.49 2.49 0.62 39.9
5 2.49 4.98 4.98 2.49 2.49 4.98 1.25 > 199.4
6 1.18 4.70 2.35 2.35 4.70 4.70 0.59 24.5
7 2.58 5.17 2.58 5.17 5.17 5.17 0.65 > 206.8
8 2.45 4.91 4.91 4.91 4.91 4.91 0.61 > 196.3
9 2.68 5.36 5.36 5.36 5.36 2.68 0.67 > 214.4
10 1.14 4.57 2.28 4.57 4.57 4.57 0.57 > 182.6
11 1.28 5.14 5.14 5.14 5.14 5.14 0.64 > 205.5
12 2.57 5.14 5.14 5.14 2.57 5.14 1.28 > 205.5
13 2.57 2.57 5.14 5.14 1.28 5.14 0.64 > 205.5
14 2.63 2.63 2.63 5.25 1.31 5.25 0.66 > 210.1
15 2.63 5.25 5.25 2.63 1.31 5.25 1.31 > 210.1
16 1.22 4.90 2.45 4.90 1.22 4.90 1.22 > 195.9
17 2.52 5.05 2.52 2.52 1.26 2.52 0.63 > 201.8
18 2.72 5.44 2.72 2.72 1.36 5.44 5.44 78.3
19 2.40 4.80 4.80 2.40 4.80 2.40 4.80 > 192.2
20 2.40 4.80 4.80 2.40 4.80 4.80 4.80 > 192.2
21 2.60 5.20 2.60 2.60 5.20 2.60 5.20 > 208.1
22 2.67 2.67 5.35 5.35 5.35 5.35 5.35 70.6
23 2.82 5.65 1.41 2.82 5.65 5.65 5.65 > 226
24 2.79 5.59 1.40 2.79 2.79 2.79 2.79 96.1
25 2.71 5.42 2.71 2.71 5.42 2.71 2.71 45.5
26 2.73 2.73 2.73 2.73 5.46 5.46 5.46 35.6
Ofloxacin 1.73 3.46 3.46 1.73 3.46
Fluconazole 4.08 2.04
5-FU 29.2